uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
June 17 2020 - 4:05PM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced the appointment of Leonard E. Post, Ph.D. to
its Board of Directors. Dr. Post, who will also chair the Company’s
Research & Development Committee, has extensive biotechnology
industry experience including previous global R&D leadership
roles at BioMarin and Onyx Pharmaceuticals.
"It is with great pleasure that we nominate Len
to the uniQure board,” stated Matthew Kapusta, chief executive
officer of uniQure. “His considerable biotechnology
experience, including his important work in gene therapy, are
valuable assets for uniQure as we work to advance our pipeline
candidates and to prepare to file for marketing authorization of
etranacogene dezaparvovec in hemophilia B.”
Since 2016, Dr. Post has served as Chief
Scientific Officer of Vivace Therapeutics and its sister company,
Virtuoso Therapeutics, both of which are developing oncology
therapeutics. From 2010 until 2016, Dr. Post served in various
positions at BioMarin (NASDAQ: BMRN), including
Chief Scientific Officer, during which time he oversaw the
initiation of BioMarin's first gene therapy project for hemophilia
A. Prior to that, Dr. Post served as Chief Scientific Officer
of LEAD Therapeutics, Senior Vice President of Research &
Development at Onyx Pharmaceuticals and Vice President of Discovery
Research at Parke-Davis Pharmaceuticals. He is also currently an
advisor to Canaan Partners.
Dr. Post is a virologist by training and did
early work on engineering of herpes simplex virus as a postdoctoral
fellow. He has a Bachelor of Science degree in Chemistry from
the University of Michigan, and a Doctorate degree in Biochemistry
from the University of Wisconsin.
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. We
are leveraging our modular and validated technology platform to
rapidly advance a pipeline of proprietary gene therapies to treat
patients with hemophilia B, hemophilia A, Huntington's disease,
Fabry disease, spinocerebellar ataxia Type 3 and other
diseases. www.uniQure.com
uniQure Contacts:
FOR
INVESTORS: |
|
FOR
MEDIA: |
|
|
|
Maria E. Cantor |
Chiara E. Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: 617-306-9137 |
Mobile: 339-223-8541 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0364d19c-b363-46bb-9277-8e349f7661fd
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024